Acceleron and Celgene Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration
News Mar 25, 2008
Acceleron Pharma, Inc. has announced it has received the upfront payment from Celgene Corporation following clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for the collaboration between the two companies previously announced on February 20, 2008.
The collaboration between Acceleron and Celgene is a joint development, joint commercialization agreement on ACE-011, a first-in-class, novel bone-forming compound, and three discovery stage programs for the treatment of cancer and cancer-related bone loss.
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE